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Abstract
The activatedmutants of the α-subunits of G proteins G12 and G13 have been designated as the gep oncogenes owing
to their ability to stimulate diverse oncogenic signaling pathways that lead to neoplastic transformation of fibroblast
cell lines and tumorigenesis in nude mice models. Studies from our laboratory as well as others have shown that the
growth-promoting activities of Gα12 and Gα13 involve potent activation of c-Jun N-terminal kinases (JNKs). Our previ-
ous studies have indicated that the JNK-interacting leucine zipper protein (JLP), a scaffold protein involved in the struc-
tural and functional organization of the JNK/p38 mitogen-activated protein kinase module, tethers Gα12 and Gα13 to
the JNK signaling module. In the present study, in addition to demonstrating the physical association between JLP
and Gα12, we show that this interaction is enhanced by the receptor- or mutation-mediated activation of Gα12. We also
establish that JLP interacts with Gα12 through the C-terminal domain that has been previously identified to be involved
in binding to Gα13. Furthermore, using this C-terminal domain as a competitively inhibitor of JLP that can disrupt Gα12-
JLP interaction, we demonstrate that JLP is required for the stimulation of JNK by Gα12. Our results also indicate that
such JLP interaction is required for Gα12 as well as Gα13-mediated neoplastic transformation of JLP. These studies
demonstrate for the first time a functional role for JLP in the gep oncogene–regulated neoplastic signaling pathway.
Neoplasia (2011) 13, 358–364
Introduction
The gep oncogenes, defined by the activated mutants of Gα12 and
Gα13 [1,2], stimulate critical signaling pathways involved in cell
growth, differentiation, and apoptosis [3–10]. Analyses of Gα12/13-
mediated cell proliferation, differentiation, and apoptosis have identi-
fied that the activation of c-Jun N-terminal kinase (JNK) plays a central
role in all of the critical pathways activated by Gα12/13 [2,3,7,11].
Our previous studies have shown that JNK-interacting leucine zipper
protein (JLP) acts as a scaffold in linking Gα12 and Gα13 to the
JNK signaling module [12]. Although these initial studies indicated
the association between JLP and Gα12 or Gα13, the functional con-
sequence of the interaction remains far from clear. Considering the
observations that JNK plays a critical role in Gα12-mediated cell pro-
liferation [6,11,13,14], we sought to investigate the role of JLP in
Gα12-mediated activation of JNK and neoplastic transformation. In this
report, we present our findings that JLP interacts with Gα12 through
a specific C-terminal domain–similar to Gα13—and this interaction
promotes Gα12-mediated activation of JNK. Furthermore, we demon-
strate that the coexpression of JLP along with Gα12 greatly enhances
the ability of Gα12 to induce neoplastic transformation of NIH3T3
cells and the expression of the dominant negative inhibitory mutant
of JLP drastically decreases the transforming ability of activated Gα12
as well as Gα13. Thus, our findings presented here for the first time
demonstrate a unique role for JLP in the oncogenic pathway(s) activated
by the gep oncogenes.
Abbreviations: JNK, c-Jun N-terminal kinase; JLP, JNK-interacting leucine zipper
protein; MAPK, mitogen-activated protein kinase
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Materials and Methods
Cells, Plasmids, and Transfections
NIH3T3 and COS-7 cells were maintained in Dulbecco modified
Eaglemedium (InvitrogenLifeTechnologies, Inc,Carlsbad,CA) contain-
ing 10% fetal bovine serum (Invitrogen Life Technologies) and 1% peni-
cillin/streptomycin at 37°C in a 5% CO2 incubator. Expression vectors
encoding S-epitope–tagged JLP, its mutant derivatives, Gα12, and Gα13
constructs have been previously described [3,10]. Transfection of COS-7
cells was carried out using FuGENE-6 reagent (Roche Applied Sciences,
Indianapolis, IN) according to the manufacturer’s protocol. Transfection
of NIH3T3 cells was carried out using calcium phosphate precipitation
method following the previously published procedures [9,12].
Coprecipitation and Immunoblot Analysis
Coprecipitation studies were carried out with COS-7 cells using
S-protein agarose (Novagen, EMD Biosciences, Inc, Madison, WI)
or antibodies specific to proteins of interest followed by protein A
Sepharose beads (Amersham Biosciences Corp, Piscataway, NJ) as fol-
lows. For coprecipitation analyses with S-tagged JLP constructs, cells
were lysed at 24 hours after transfection, and the lysate protein (500 μg
each) was incubated with 30 μl of S-protein agarose for 4 hours at 4°C.
After repeated washes with lysis buffer, the S-protein agarose–bound
proteins were separated by SDS-PAGE and electroblotted on to poly-
vinylidene difluoride membranes for immunoblot analysis. Immunoblot
analyses of lysates or immunoprecipitated proteins were carried out
according to previously published procedures [9,12]. For immuno-
precipitation analyses, cell lysate protein (500μg each)was incubatedwith
1μg of respective antibodies for 4 hours at 4°C followed by the addition of
20 μl of 50% slurry of protein A Sepharose. After repeated washes with
cell lysis buffer, the immunoprecipitated proteins were separated by SDS-
PAGE and electroblotted onto polyvinylidene difluoride membranes for
immunoblot analysis. Antibodies to HA epitope (2362) and phosphory-
lated JNK (9251) were obtained from Cell Signaling Solutions (Beverly,
MA), whereas antibodies to S-epitope (sc-802), JNK-1 (sc-474), and
Gα12 (sc-409) were obtained from Santa Cruz Biotechnology, Inc (Santa
Cruz, CA). For immunoblot analyses with Gα13, antibodies raised
against the C-terminus of Gα13 (AS1-89-2) that has been previously de-
scribed were used [15]. After washing the immunoprecipitates twice with
lysis buffer, the immunoprecipitated proteins were separated by SDS-
PAGE and electroblotted on to PVDFmembranes. Immunoblot analyses
with specific antibodies were carried out following the previously pub-
lished procedures [12].
Focus Formation Assay
NIH3T3 cell focus formation assay was carried out as previously de-
scribed [9]. Parental NIH3T3 cells were transfected with pcDNA3 vec-
tors encoding Gα12QL or Gα13QL (5 μg) along with or without pSG5
vector encoding JLP and different domain constructs of JLP including
GID-JLP (5 μg) using the calcium phosphate transfection method.
Control group included the transfections with empty pcDNA3 vector
(10 μg). Transfected NIH3T3 cells were cultured in the presence of 5%
serum, and transformed foci were stained and scored after 14 days.
Results
Interaction between the gep Oncogene Gα12 and JLP
Our previous findings have shown that both Gα12 and Gα13 physi-
cally associate with JLP [12]. To analyze this further, especially the
interaction between JLP and Gα12, we investigated whether the inter-
action is dependent on the activated status of Gα12. To test, COS-7
cells were cotransfected with pSG5-vector encoding S-protein epitope–
tagged JLP (S-JLP) and pcDNA3 vector encoding Gα12WT or con-
stitutively activated, GTPase-deficient mutant of Gα12QL. Transfec-
tants were lysed at 48 hours, and the cell lysates were subjected to an
S-protein agarose pull-down assay followed by immunoblot analysis
with antibodies-specific to Gα12. Results from such analysis indicated
the presence of Gα12 in JLP precipitates, thereby confirming our pre-
vious findings that Gα12 physically associates with JLP (Figure 1A).
More interestingly, the levels of JLP pulled down from cells express-
ing Gα12QL showed an increase—although modest—in the associated
Gα12 levels compared to that of wild-type Gα12 (lane 2 vs lane 3), in-
dicating that the activated Gα12 more preferentially interacts with JLP.
To establish further that the activated conformation of Gα12 interacts
more efficiently with JLP, we investigated whether receptor-mediated
activation of Gα12 promotes an increase in its association with JLP.
Therefore, we tested whether lysophosphatidic acid (LPA), which acti-
vates Gα12/13 through specific LPA receptors, can stimulate the associa-
tion of Gα12 and JLP. Because COS-7 cells that are known to express
LPARs [16], these cells were transfected with vectors encoding S-JLP
and Gα12WT. At 24 hours after transfection, the transfectants were
serum starved for 24 hours after which they were stimulated with
20 μM LPA for 10 minutes. The lysates from these transfectants were
subjected to S-protein agarose precipitation. The S-protein agarose pre-
cipitates were analyzed for the presence of Gα12 by immunoblot analy-
ses using Gα12-specific antibodies. As shown in Figure 1B, stimulating
the transfectants with LPA increased the levels of Gα12 that get co-
precipitatedwith S-JLP.Together with the increased association seenwith
mutationally activated Gα12 (Figure 1A), these results suggest that both
the mutational and receptor-mediated activation of Gα12 can enhance
its interaction with JLP.
Mapping the Gα12-Interacting Domain of JLP
As a scaffold protein involved in JNK/p38 mitogen-activated protein
kinase (MAPK) signaling, JLP contain specific motifs such as SH2, SH3,
and leucine zipper domain to tether the functional constituents of the
JNK module [17]. Previously, we have shown that the JNK-, KLC-1–,
Gα13-, and SCG10-interacting domains of JLP can be mapped to dis-
tinct nonoverlapping regions of JLP [12,17–19]. Therefore, we were in-
terested in determining whether JLP interacts with Gα12 through any of
these known domains or a distinctly different one. To test, we analyzed
its interactions with Gα12 using S-tagged constructs encoding distinct
domains of JLP (Figure 2A). COS-7 cells were transfected with vector
encoding the constitutively active Gα12QL along with S-tagged mutant
constructs with different JLP domains for 48 hours. The transfectants
were lysed and the lysates were precipitated with S-protein agarose beads,.
and the presence of Gα12 in the precipitates was examined by immuno-
blot analysis using an antibody specific to Gα12. Results from this analy-
sis indicated that Gα12 could be coprecipitated with S-JLP only from the
transfectants expressing the extreme C-terminal domain of JLP spanning
amino acids 1165-1307 (Figure 2B). Thus, these results demonstrate
that JLP interacts with Gα12 through its extreme C-terminal domain,
spanning 1165 to 1307 amino acids (domain IV). Interestingly, this is
the same domain that was previously identified to be involved in JLP’s
interaction with Gα13 [12]. Thus, the C-terminal domain encompassing
1165-1307 amino acids of JLP that was previously referred as Gα13-
interacting domain of JLP (GID-JLP) turns out to be an interacting do-
main for both Gα12 and Gα13.
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JLP Enhances Gα12 Activation of JNK
Based on the findings that 1) Gα12 interacts with JLP through the
extreme C-terminal GID domain and 2) JLP interacts with JNK
through the N-terminal domain [17], it can be hypothesized that
JLP tethers Gα12 to the JNK module, thereby promoting its ability
to stimulate the JNK module. If this hypothesis is true, cotransfection
of JLP should enhance Gα12-mediated JNK response, whereas the
inhibition of such interaction should attenuate Gα12-mediated activa-
tion of JNK. In fact, our previous studies have shown that the co-
expression of JLP stimulates LPA as well as Gα13-mediated activation
of JNK, whereas the coexpression of GID-JLP inhibits such activation
[12]. To test whether the same holds true for Gα12, COS-7 cells were
transfected with the activated mutant of Gα12 (Gα12QL) in the ab-
sence or presence of JLP for 48 hours. The lysates from these trans-
fectants were resolved by SDS-PAGE and subjected to immunoblot
analysis using antibodies specific to the phosphorylated forms of JNK
to monitor their activation profile. Results indicated that Gα12 stimu-
lated an increase in the activation of JNK (Figure 3, lane 3), and this
could be further enhanced by the coexpression of JLP (Figure 3A, lanes
5 and 6), thus suggesting that JLP plays a potentiating role in the Gα12-
mediated activation of JNK signaling module. In contrast, when COS-7
cells were transiently transfected with vectors encoding Gα12QL along
with S-epitope–tagged GID-JLP for 48 hours, Gα12-stimulated increase
in the activation of JNK (Figure 3B, lane 2) was attenuated by the co-
expression of GID-JLP (Figure 3B, lane 6). Taken together, these results
establish a cardinal role for JLP in Gα12-mediated stimulation of JNK.
JLP Is Involved in gep Oncogene–Mediated
Neoplastic Transformation
Our findings that JLP potentiates Gα12-mediated activation of
JNK gains greater significance in light of the previous observation
from our laboratory as well as others that JNK plays a critical role in
Gα12-mediated mitogenic signaling pathways [3,5,6,10]. Therefore,
Figure 1. Gα12 interacts with JLP. (A) COS-7 cells were cotransfected with vectors encoding S-JLP along with wild-type form (Gα12WT) or
constitutively active form (Gα12QL) of Gα12 expression constructs. Lysates were collected after 48 hours, and the pull-down assay was
carried out using S-agarose beads. Immunoblot analysis was carried out to assess the presence of Gα12 in the S-JLP precipitates, using
an antibody specific to Gα12. Expression levels of JLP and Gα12 were monitored by immunoblot analysis with Gα12 or S-protein antibody.
Results form a typical experiment presented here (n = 3). (B) COS-7 cells were cotransfected with vectors encoding S-JLP along with wild-
type form (Gα12WT). Transfectants were serum-starved for 24 hours after which the cells were stimulatedwith 20 μMof LPA for 10minutes.
After LPA stimulation, cells were lysed, and the lysates were subjected to S-agarose pull-down assay. Immunoblot analysis was carried out
to assess the presence of Gα12 in the S-JLP precipitates, using an antibody specific to Gα12. Expression levels of JLP and Gα12 were moni-
tored by immunoblot analysis with Gα12 or S-protein antibody. Results form a typical experiment from a set of three repeats.
Figure 2. Gα12 interacts with the C-terminal domain of JLP. (A) Sche-
matic diagram representing JLPdeletionmutant constructs encoding
different domains. These constructs encode S-tagged JLP-domain I
(amino acids 1-164), II (amino acids 165-473), IIΔ (amino acids 210-
398), III (amino acids 465-1008), C (amino acids 997-1170), and IV
(amino acids 1165-1307). (B) Vector constructs expressing Gα12QL
were coexpressed with the different domain mutants of S-JLP in
COS-7 cells. After 48 hours, the lysates were subjected to the pull-
down assay with the S-protein agarose beads. The coprecipitated
Gα12 was identified by immunoblot analysis using antibodies to
Gα12. (C) The expression levels of transfected Gα12QL and JLP con-
structs were monitored by immunoblot analyses using antibodies to
Gα12 (upper panel) or S-tag (lower panel).
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we focused on evaluating whether the inhibition of Gα12-mediated
JNK response by the coexpression of GID-JLP would attenuate the
neoplastic transformation mediated by the either of the gep oncogenes.
Neoplastic transformation of NIH3T3 fibroblast cells and subsequent
foci formation have been widely used to monitor the oncogenic po-
tential of different oncogenes including Gα12/13 [20–24]. To carry
out this analysis, NIH3T3 cells were transfected with vectors encoding
Gα12QL, full-length JLP, and GID-JLP alone or in combinations. At
14 days after transfection, the number of foci formed was scored by
fixing the cells using glutaraldehyde followed by crystal violet staining.
Our results indicated that the expression of Gα12QL induces foci for-
mation in NIH3T3 cells confirming the previous results from several
laboratories including ours [22–24]. The foci formation was greatly in-
creased by the coexpression of JLP. Quite significantly, the coexpression
of GID-JLP drastically inhibited the number of foci formed compared
withGα12QL alone (Figure 4).More interestingly, the inhibitory effect of
GID-JLP can be neutralized by the coexpression of full-length JLP (Fig-
ure 4), thereby establishing the critical role of JLP inGα12-mediated neo-
plastic transformation.Quantification of the foci from repeat experiments
indicated that the number of foci induced by Gα12QL was increased by
the coexpression of by 90%. In contrast, the coexpression of the domi-
nant negative GID-JLP reduced Gα12QL-induced foci formation by
70%. Interestingly, the coexpression of JLP along with GID-JLP rescued
such GID-JLP mediated inhibition. Similar results were obtained using
Gα13QL, which is known to involve JNK signaling interacting with JLP
(Figure 5A). Taken together, these results suggest that a functional inter-
action between Gα12/13 and JLP is involved in neoplastic transformation
mediated by the gep oncogenes. These results for the first time identify a
novel role for JLP in the oncogenic pathways induced by the gep onco-
genes Gα12QL and Gα13QL.
Discussion
Members of the gep oncogene family, defined by the activated mutants
of Gα12 and Gα13, are the most potent G protein subunits that have
been observed to promote oncogenic signaling [2]. It has been dem-
onstrated that the activation JNK is critically required for the G1-S
transition stimulated by Gα12/13 [6,10]. It has also been observed that
Gα12 differentially regulates JNK, extracellular signal–regulated kinase,
and p38MAPK modules [25]. Whereas these findings suggested the
role for MAPKs, specifically JNK in the oncogenic signaling by the
gep oncogenes, the possible role of a specific scaffold protein that can
tether Gα12 or Gα13 to MAPK signaling is largely not understood until
now. Our observation presented here demonstrating a novel interaction
between Gα12 and the JNK scaffold protein JLP and (Figures 1–3) as
well as the critical role of JLP in Gα12/13-mediated oncogenic signaling
pathway (Figure 4) confirms and identifies JLP as a scaffold protein
involved in G12/13-mediated oncogenic signaling.
Our results also identify the C-terminal region of JLP, spanning
amino acids 1165-1307, as the critical domain of interaction with Gα12
(Figure 2). It is significant to note here that we have previously estab-
lished this region as the domain that interacts with Gα13 and hence
referred to it as the Gα13-interacting domain of JLP. Our present find-
ing redefines this region as the domain that can interact with both Gα12
and Gα13. Similar to our previous results obtained with Gα13, we
have shown here that the coexpression of JLP enhances Gα12-mediated
JNK activation, whereas the overexpression of GID-JLP inhibits JNK
activation. The fact that JLP interacts with both Gα12 and Gα13
through a single domain may be indicative that JLP binding to these
α-subunits is mutually exclusive. If so, this would mean that the JLP
interaction with Gα12 or Gα13 might be cell type– and/or context-
specific. In this context, it should be noted here that JLP has been
shown to interact with kinesin light chain 1 and this interaction has
been ascribed to play a role in spatial regulation of JLP-associated sig-
naling molecules [18]. This raises an interesting possibility that the
spatiotemporal context involving JLP and its interacting proteins may
determine whether JLP interacts with Gα12 or Gα13. Further studies
should clarify whether such context-specific events determine which
member of the gep oncogenes interacts JLP in vivo. Another set of ob-
servations that can support such context-specific signaling is our present
observation that JLP is involved in Gα12/13-mediated neoplastic trans-
formation of NIH3T3 cells (Figures 4 and 5) in conjunction with our
previous findings demonstrating that JLP is involved in Gα13-specific
retinoic acid–mediated endodermal differentiation of P19 embryonic
carcinoma cells [26]. In this regard, the scaffolding role of JLP can be
equated to the context-specific signaling role observed with the yeast
MAPK scaffold protein Ste5 [27–29]. In yeast, upon stimulated by the
Figure 3. JLP enhances Gα12-mediated activation of JNK. (A) COS-7
cells were transiently transfected with pcDNA3 vector control, wild-
type (Gα12WT), or constitutively active (Gα12QL) forms of Gα12 alone
or along with JLP. Cells were collected after 48 hours of transfec-
tion. These lysates were subjected to immunoblot analysis with anti-
bodies to phospho-specific JNK to assess its activation profile. After
stripping, the blot was reprobed with JNK antibody to monitor equal
expression levels of JNK. (B) COS-7 cells were cotransfected with
constructs expressing JNK, Gα12QL, and full-length S-JLP or mutant
GID-JLP (bearing amino acids 1165-1307). Total cell lysates were
subjected to immunoblot analysis and assessed for JNK phosphory-
lation using phospho-JNK antibody. Cell lysates were also analyzed
for the expression of HA-JNK, Gα12, full-length S-JLP, and mutant
GID-JLP with their respective antibodies.
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Figure 4. Effect of JLP and GID-JLP on Gα12QL-mediated foci formation. Parental NIH3T3 cells were transfected with empty vector pcDNA3
(VC), Gα12QL, full-length JLP (FL-JLP), Gα12QL + FL-JLP, GID-JLP, Gα12QL + GID-JLP, or Gα12QL + GID-JLP + FL-JLP using the calcium
phosphate transfection method. (A) The representative foci formed at 14 days were stained photographed (4×). Results presented are from
a typical experiment (n = 4). (B) The foci formed from four independent experiments were scored and plotted (mean ± SD).
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mating pheromone, the scaffold protein Ste5 nucleates the assembly of
the β-subunit of heterotrimeric G protein GPA (Gβ) to a kinase module
consisting of MAP4K,MAP3K,MAP2K, defined by Ste20, Ste 11, Ste7
to activate Fus3, a MAPK [30,31]. Interestingly, it has been shown that,
in the absence of any pheromone, Ste5 can also facilitate the assembly of
the same Gβ-Ste20-Ste11-Ste7 complex to activate Kss1, a different
MAPK, to elicit invasive growth response of haploid cells or vegetative
growth of diploid cells [27]. Thus, in this model system, the differen-
tial context-specific recruitment of the downstream MAPKs, namely,
Fus3 and Kss1 can drastically alter the final signaling outcome of the
G protein–MAPK scaffold [30]. It is likely that JLP provide such context-
specific scaffolding role for both oncogenic and differentiation by effec-
tively tethering different downstream signaling components.
In addition to these observations, careful analysis of JNK activation
by Gα12 in the presence of JLP provides novel insight into the dynamic
manner in which the scaffold protein such as JLP modulates the activity
of the associated kinase. Whereas the expression of Gα12 or Gα12QL
along with JLP leads to the maximal activation of JNK (Figure 3A,
lanes 5 and 6), coexpression of epitope-tagged JNK seems to elicit
only a moderate activation of JNK by Gα12QL (Figure 3B, lane 2 vs
lane 5). It is quite possible that the overexpression of JNK and the re-
sultant increase in the basal levels of activated JNK (Figure 3B, lane 1)—
possibly forming endogenous competing signaling complexes—leads to
the squelching of Gα12QL-JLP signaling. Further characterization of
JLP and its interacting proteins should provide finer details on the dy-
namics of JLP and Gα12 interaction in the activation of JNK. Never-
theless, the observation that the coexpression of GID-JLP attenuates
Gα12QL-stimulated JNK activity to basal levels (Figure 3B, lanes 3 vs
6 ) further confirms the crucial role played by JLP in Gα12-mediated
activation of JNK.
Finally, our results presented here point to a critical pathobiological
role JLP can play in the oncogenic pathway stimulated by LPA. It has
been well established that LPA plays a critical role in the genesis and
progression of many different cancers [32–35]. It has also been shown
that LPAR-deficient mouse embryonal fibroblasts show deficiency in
the activation of JNKs. In this context, our observation that LPA stim-
ulates the association of JLP to Gα12 (Figure 1B) and our previous
findings that LPA-stimulated JNK activity can be inhibited by the ex-
pression of GID-JLP that can inhibit JLP-Gα12/13 interaction [12] gain
greater significance. The observations that 1) LPA signaling is involved
in the pathophysiology of many cancers [32–35], 2) LPA potently stimu-
lates the gep oncogenes Gα12/13 [13], 3) LPA stimulates the association
between Gα12 and JLP (Figures 1 and 2), and 4) both LPA- [12] and
Gα12-mediated stimulation of JNK is inhibited by GID-JLP (Figures 3
and 4) suggest a key role JLP in LPA-Gα12/13–mediated oncogenic path-
way. The observation that JLP plays a critical role in Gα12/13-mediated
neoplastic transformation (Figures 4 and 5) provides additional support
for this view. Now that such basic paradigm is established, further studies
should clarify the critical role of Gα12/13 and JLP in LPA-promoted me-
diated tumorigenesis and tumor progression.
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